



Final Appraisal Recommendation

Advice No: 2413 – October 2013

Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (Stribild[®]▼) 150 mg/150 mg/200 mg/245 mg film-coated tablets

Submission by Gilead Sciences Ltd

Recommendation of AWMSG

Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (Stribild[®]▼) is recommended as an option for use within NHS Wales for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over who are antiretroviral-treatment-naïve or are infected with HIV-1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild[®]▼.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1446), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue:	Gilead Sciences Ltd
Date of first issue	October 2013
Last reviewed	December 2016

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2413:
Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (Stribild[®]▼)
150 mg/150 mg/200 mg/245 mg film-coated tablets. October 2013.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.